Study of SGR-1505 in Mature B-Cell Neoplasms

• Status: Not yet recruiting
• Trial end date: 2024-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-1505.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Schrödinger, Inc.

Criteria

Inclusion Criteria:

• Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy.

• Subject must have measurable or detectable disease according to the applicable disease-specific classification system.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

• Life expectancy ≥ 12 weeks.

Exclusion Criteria:

• For a subject with indolent NHL and CLL/SLL, the subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit) and has an indication for treatment.

• Subject has previous invasive malignancy in the last 2 years.

• Subject has a known allergy to SGR-1505 or excipients of SGR-1505.

• Subject has symptomatic or active CNS involvement of disease.

• Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.